Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The National Institutes of Health PubMed database maintains the growing body of peer-reviewed literature on triple-agonist metabolic compounds, including retatrutide primary and secondary research
The STEP 1 trial demonstrated nearly 15% average body weight loss at 68 weeks, with more than 86% of participants losing at least 5% and roughly one-third losing 20% or more
Who are these treatments for
As a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide enhances insulin secretion, suppresses glucagon release, and slows gastric emptying
To combat diabetes and obesity, providers and patients are turning to prescription medications such as glucagon-like peptide-1 (GLP-1) receptor agonists
